New in Medical Technology

Labopharm files New Drug Submission with Health Canada for novel antidepressant

LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel formulation of the antidepressant trazodone. "We are pleased to file our New Dru...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

PHOENIX, Aug. 3 /PRNewswire-USNewswire/ -- The Phoenix-based Kronos Longevity Research Institute (KLRI) has published two new publications on hormone therapies and their effects on reducing the risks of cardiovascular disease in older adults. Cardiovascular disease caused by ...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

FRANKLIN LAKES, N.J., July 30 /PRNewswire-FirstCall/ -- A new analysis finds that women in New Jersey who take the breast cancer drug tamoxifen in conjunction with certain popular antidepressants may be at a higher risk for a breast cancer recurrence. In May, Medco Health Solutions, ...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

New agreement outlines an increased level of commitment to clinical care, research and education NEW YORK, July 30 /PRNewswire-USNewswire/ -- Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University today announced a new ten-year agreement to continue t...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

ENGLEWOOD CLIFFS, N.J., July 27 /PRNewswire/ -- Until now, all regular body washes caused dry skin damage. Now, Dove has discovered how to restore skin's natural moisture while cleansing with body wash. Current body washes actually damage proteins and lipids in the skin's outer lay...

Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today during a lease signing event that it has become the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a development that sh...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...

Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program

FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

VIENNA, July 15 /PRNewswire-USNewswire/ -- This week, more than 3,000 leading scientists convened to report and discuss the latest advances in research on treatments, risk factors, diagnosis and causes for the health epidemic of the 21st century -- Alzheimer's disease -- at the Alzheimer's As...

Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris

VANCOUVER, July 13 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the c...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammat...

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development pr...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

REYKJAVIK, Iceland, July 1 /PRNewswire-FirstCall/ -- The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational consortium of s...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of impro...

CEL-SCI Posts New Corporate Presentation to Website

VIENNA, Va., June 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ) announced today that a new corporate presentation is available for review on the Company's website at http://www.cel-sci.com/investor_relations.html . The presentation includes information on CEL-SCI...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

ROCKVILLE, Md., June 16 /PRNewswire-USNewswire/ -- According to a new report by HHS' Agency for Healthcare Research and Quality, there is insufficient evidence to conclude that genetic testing for two gene mutations in adults with a history of blood clots helps to prevent a condition known as deep...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

Studies Advocate Blood Conservation and Appropriate Indicators for Transfusion IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies - ...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

New Insights into the Prediction of IBD Using Serology Testing Also Presented SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the det...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

Data Presented at 45th American Society of Clinical Oncology Annual Meeting Abstracts: 5033, 3560 ORLANDO, Fla., May 30 /PRNewswire/ -- Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor ...

Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

Abstract # 25670 ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer research conducted at the Barbara Ann Karmanos Cancer Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking fi...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

BOSTON, May 29 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL ), today announced the launch of a website designed to help investigators apply the new 1.1 version of RECIST (...

BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug

TURKU, Finland, May 28 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure...

Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development

Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett's esophagus in randomized, multicenter, sham controlled trial SUNNYVALE, Calif., May 27 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine rev...

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338

-Clinical study planned for relapsed / refractory acute myelogenous leukemia- PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FD...

Creighton Medical Laboratories First to Offer New Cancer Test

OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first clinical laboratory worldwide to offer a new and more effective testing method for cancer. The method, called SNP arra...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- ...

Spherix Elects New Independent Director, and Elects Chairman of the Board

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that, on May 1...

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for...

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and ps...

VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful

WASHINGTON, May 12 /PRNewswire/ -- The Epilepsy Foundation recently announced findings that show people with epilepsy, whose seizures have been controlled with a consistent drug therapy, have a greater chance of increased seizures, greater side effects or sudden death when their medications are sw...

ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services

NORFOLK, Va., May 8 /PRNewswire/ -- ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, announces its support for the use of The Joint Commission's Hospital-Based Inpatient Psychiatric Services (HBIPS) performance measures. The basis for the recently c...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

JACKSONVILLE, Fla. and ALEXANDRIA, Va., May 8 /PRNewswire-USNewswire/ -- New recommendations released today by a consensus group of the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) are calling for major changes in the way health care professi...

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

Data from landmark trial provide important insight for physicians in treating heart attack patients NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New...